$ETST’s President, Director, & COO concludes with, “Gabriel has done a remarkable job building our sales team and expanding our presence across the U.S. I have no doubt that 2018 is going to be a solid year of growth for us, with all we have initiating as early as January alone, with our CBD products. Our MSN-2 medical device globalization strategy is still on track, and we are currently in talks with institutional investors thanks to our planned up-listing in Q1 2018. I plan on sharing further updates as they progress on the MSN-Medical device, IP patents, CBD based pharmaceutical generic drugs, and our new CBD formula opioid clinical trials as they progress.”